FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200915536> ?p ?o ?g. }

• W3200915536 endingPage "184" @default.
• W3200915536 startingPage "174" @default.
• W3200915536 abstract "This pre-specified analysis of DAPA-CKD assessed the impact of sodium-glucose cotransporter 2 inhibition on abrupt declines in kidney function in high-risk patients based on having chronic kidney disease (CKD) and substantial albuminuria. DAPA-CKD was a randomized, double-blind, placebo-controlled trial that had a median follow-up of 2.4 years. Adults with CKD (urinary albumin-to-creatinine ratio 200-5000 mg/g and estimated glomerular filtration rate 25-75 mL/min/1.73m2) were randomized to dapagliflozin 10 mg/day matched to placebo (2152 individuals each). An abrupt decline in kidney function was defined as a pre-specified endpoint of doubling of serum creatinine between two subsequent study visits. We also assessed a post-hoc analysis of investigator-reported acute kidney injury-related serious adverse events. Doubling of serum creatinine between two subsequent visits (median time-interval 100 days) occurred in 63 (2.9%) and 91 (4.2%) participants in the dapagliflozin and placebo groups, respectively (hazard ratio 0.68 [95% confidence interval 0.49, 0.94]). Accounting for the competing risk of mortality did not alter our findings. There was no heterogeneity in the effect of dapagliflozin on abrupt declines in kidney function based on baseline subgroups. Acute kidney injury-related serious adverse events were not significantly different and occurred in 52 (2.5%) and 69 (3.2%) participants in the dapagliflozin and placebo groups, respectively (0.77 [0.54, 1.10]). Thus, in patients with CKD and substantial albuminuria, dapagliflozin reduced the risk of abrupt declines in kidney function." @default.
• W3200915536 created "2021-09-27" @default.
• W3200915536 creator A5008309890 @default.
• W3200915536 creator A5012551917 @default.
• W3200915536 creator A5016452405 @default.
• W3200915536 creator A5029467844 @default.
• W3200915536 creator A5034939991 @default.
• W3200915536 creator A5041913215 @default.
• W3200915536 creator A5048450888 @default.
• W3200915536 creator A5052533254 @default.
• W3200915536 creator A5060560730 @default.
• W3200915536 creator A5062276281 @default.
• W3200915536 creator A5067426250 @default.
• W3200915536 creator A5069865054 @default.
• W3200915536 creator A5078418468 @default.
• W3200915536 creator A5084032669 @default.
• W3200915536 creator A5085592050 @default.
• W3200915536 creator A5085677017 @default.
• W3200915536 creator A5088177327 @default.
• W3200915536 date "2022-01-01" @default.
• W3200915536 modified "2023-10-18" @default.
• W3200915536 title "A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function" @default.
• W3200915536 cites W1888211049 @default.
• W3200915536 cites W2001820152 @default.
• W3200915536 cites W2079079821 @default.
• W3200915536 cites W2082505416 @default.
• W3200915536 cites W2129721911 @default.
• W3200915536 cites W2136709241 @default.
• W3200915536 cites W2148001954 @default.
• W3200915536 cites W2155749392 @default.
• W3200915536 cites W2273304042 @default.
• W3200915536 cites W2749798950 @default.
• W3200915536 cites W2766009796 @default.
• W3200915536 cites W2799500201 @default.
• W3200915536 cites W2884817413 @default.
• W3200915536 cites W2888098196 @default.
• W3200915536 cites W2890282628 @default.
• W3200915536 cites W2971414122 @default.
• W3200915536 cites W3015103140 @default.
• W3200915536 cites W3026804276 @default.
• W3200915536 cites W3035468154 @default.
• W3200915536 cites W3044947482 @default.
• W3200915536 cites W3088173406 @default.
• W3200915536 cites W3092582090 @default.
• W3200915536 cites W3096486083 @default.
• W3200915536 cites W3103002140 @default.
• W3200915536 cites W3110989969 @default.
• W3200915536 cites W3114937304 @default.
• W3200915536 cites W3120289699 @default.
• W3200915536 cites W3126779683 @default.
• W3200915536 cites W3174145401 @default.
• W3200915536 doi "https://doi.org/10.1016/j.kint.2021.09.005" @default.
• W3200915536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34560136" @default.
• W3200915536 hasPublicationYear "2022" @default.
• W3200915536 type Work @default.
• W3200915536 sameAs 3200915536 @default.
• W3200915536 citedByCount "43" @default.
• W3200915536 countsByYear W32009155362021 @default.
• W3200915536 countsByYear W32009155362022 @default.
• W3200915536 countsByYear W32009155362023 @default.
• W3200915536 crossrefType "journal-article" @default.
• W3200915536 hasAuthorship W3200915536A5008309890 @default.
• W3200915536 hasAuthorship W3200915536A5012551917 @default.
• W3200915536 hasAuthorship W3200915536A5016452405 @default.
• W3200915536 hasAuthorship W3200915536A5029467844 @default.
• W3200915536 hasAuthorship W3200915536A5034939991 @default.
• W3200915536 hasAuthorship W3200915536A5041913215 @default.
• W3200915536 hasAuthorship W3200915536A5048450888 @default.
• W3200915536 hasAuthorship W3200915536A5052533254 @default.
• W3200915536 hasAuthorship W3200915536A5060560730 @default.
• W3200915536 hasAuthorship W3200915536A5062276281 @default.
• W3200915536 hasAuthorship W3200915536A5067426250 @default.
• W3200915536 hasAuthorship W3200915536A5069865054 @default.
• W3200915536 hasAuthorship W3200915536A5078418468 @default.
• W3200915536 hasAuthorship W3200915536A5084032669 @default.
• W3200915536 hasAuthorship W3200915536A5085592050 @default.
• W3200915536 hasAuthorship W3200915536A5085677017 @default.
• W3200915536 hasAuthorship W3200915536A5088177327 @default.
• W3200915536 hasBestOaLocation W32009155361 @default.
• W3200915536 hasConcept C126322002 @default.
• W3200915536 hasConcept C126894567 @default.
• W3200915536 hasConcept C134018914 @default.
• W3200915536 hasConcept C142724271 @default.
• W3200915536 hasConcept C159641895 @default.
• W3200915536 hasConcept C168563851 @default.
• W3200915536 hasConcept C197934379 @default.
• W3200915536 hasConcept C203092338 @default.
• W3200915536 hasConcept C204787440 @default.
• W3200915536 hasConcept C207103383 @default.
• W3200915536 hasConcept C27081682 @default.
• W3200915536 hasConcept C2776174234 @default.
• W3200915536 hasConcept C2777180221 @default.
• W3200915536 hasConcept C2777422806 @default.
• W3200915536 hasConcept C2778653478 @default.
• W3200915536 hasConcept C2780306776 @default.
• W3200915536 hasConcept C2780472472 @default.
• W3200915536 hasConcept C44249647 @default.
• W3200915536 hasConcept C555293320 @default.

• next